1. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell. 1990, 2: 275-280.
2. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992, 148: 1274-9.
3. Nagata S: Fas and Fas ligand: a death factor and its receptor. Adv Immunol. 1994, 57: 129-44. full_text.
4. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis. Cancer Res. 1998, 58: 1741-9.
5. Von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ: Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery. 1999, 125: 73-84.